Object: 1). To analyze of serum tumor marker CA-125 in patients with ovarian malignant tumors. 2). To correlate betweenthe serum levels of tumor marker with histological types of ovarian malignant tumors. Study Design: Institution based descriptive andprospective study. Place & Duration: Department of Pathology, Liaquat University of Medical & Health Sciences, Jamshoro from January2009 to June 2011. Material & Methods: One hundred cases, diagnosed as ovarian malignant tumor on H&E staining were selected forstudy & measure serum CA-125 preoperatively and postoperatively in each case. Results: Out of 100 cases diagnosed as on H&E stainwere 33 serous cystadenocarcinoma, 24 mucinous adenocarcinoma, 10 germ cell tumors and 08 sex-cord stromal tumors. On serumanalysis increased level of CA-125 was seen preoperatively in 33/33 cases of serous cystadenocarcinoma and 24/29 cases of mucinousadenocarcinoma. Serum tumor marker value was declined following appropriate therapy of the tumors. Conclusions: Serum tumormarkers CA-125 is useful and important for the detection of ovarian tumors. It is most significant for serous cystadenocarcinoma. It mayalso help in prognosis and specific treatment of ovarian malignancies relating to histological type.
Objectives: To determine the urothelial carcinoma and its association with age and gender. Study Design: Retrospective study. Setting: Pathology department of Liaquat university of Medical and Health Science. Period: One year from January 2016 to December 2016. Material and Methods: Four micrometer thick paraffin-embedded and formalin-fixed sections were prepared from transurethral resection6of bladder6tumor (TURBT) samples of urothelial carcinoma patients and were examined. Histological grading was categorized as low and high grades. All the data was collected by self-made proforma. Data was analyzed by SPSS version 20. Results: Total 83 cases were enrolled in current study; their mean age was 49.19+12.33 years. Males were found in the majority 51(61.4%) and females were 32(38.6%). Most common age group was 46-60 years 36(43.4%). According to the histological grading high grade was most common as 65.10%, and low grade urothelial carcinoma was 34.90%. There was no significant difference according to age of histological grading. Male gender was most common, while progression of disease was higher among females in contrast to males as high grade carcinoma was significantly higher among females, p-value 0.014. Conclusion: It was concluded that male gender is the contributing factor of urothelial carcinoma, but disease progression significantly high among females. No significant association has been found according to age.
Object: Evaluation & distribution of established etiological risk factors in patientsof breast cancer in our local population. Study Design: Institution based non-interventionaldescriptive & prospective study Place & Duration: Department of Pathology, Liaquat Universityof Medical & Health Sciences, Jamshoro from January 2009 to December 2011. Material &Methods: One hundred & two cases of breast cancer diagnosed on HE staining were selected forthe study. Results: More than 50% were in 4th and 5th Decades of life. 94% were married and06% were un-married. 65% were in pre-menopausal group and 35% in post-menopause group.93% had positive history of breast feeding. None of them had ever taken oral contraceptive.Smoking history was present only in 9.80 % cases. 27% cases had family history of breast cancerin first degree relative & 13% in 2nd degree relatives. Majority (66.66%) were belongs to lowermiddle socioeconomic class. Conclusions: Surprisingly in this study marital status, parity, andbreast feeding not proved as protective factors against breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.